CARLSBAD, Calif., Nov. 14, 2018 /PRNewswire/ — EBD Group has just launched its full three-part 2018 Digital Medicine Report Series in partnership with Demy-Colton. This comprehensive report dives into the latest regulatory developments ahead of the Digital Medicine & Medtech Showcase in San Francisco Jan. 7–9, 2019.
Digital medicine—a more narrowly focused subset of digital health that encompasses products with potential for disease management—is now touching all aspects of the health ecosystem through software, medical devices, and products in the research and commercialization pipelines. These medical technologies are reimagining everything from business models and markets to standards of care, and impacting stakeholders throughout the care continuum.
Report 1 – Digital Medicine 2018: Part 1 – Innovation Supported by Regulation. The regulatory environment for digital medicine is rapidly changing, but what’s on the horizon for 2019? The first report dives into how the FDA is forging into new territory and folding digital medicine into the regulatory process.
Report 2 – Digital Medicine 2018: Part 2 – Financing the Future. Digital healthcare investments are benefiting from the surfeit of cash that is lifting the biotech sector and, in fact, all industries in 2018.
Report 3– Digital Medicine 2018: Part 3 – Securing Against Cyber Threats. From drug developers all the way to providers, it’s key to find secure ways to access and use data to improve human health, all while protecting individuals’ privacy.
In the past year, digital medicine has continued to define and refine the ways we think about health and providing care for individuals and populations. As digital therapeutic tools further differentiate themselves from consumer applications through rigorous clinical validation and pursuit of FDA approval, the boundaries of digital medicine become clearer. The field is seeing vast improvements in how products and technologies can effectively use the massive amounts of data being collected every second of every day, as well as efficiently move through the regulatory process. To learn more, download the new reports to get the scoop on the latest developments.
Digital Medicine & Medtech Showcase at Biotech Showcase™ is the premier event at the intersection of technology and medicine with rich networking opportunities to connect with investors and potential partners. Hear from 75+ companies with industry leading perspectives and request one-to-one meetings in partneringONE®. Attendees also receive full access to the Biotech Showcase program.
About EBD Group
EBD Group’s overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings.
Today our events (BIO-Europe®, BIO-Europe Spring®, BioPharm America™, Biotech Showcase™, BioEquity Europe, ChinaBio® Partnering Forum, Cell & Gene Connect, China Showcase, and Digital Medicine & Medtech Showcase) annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.
+1 760 930 0500
View original content to download multimedia:http://www.prnewswire.com/news-releases/ebd-group-and-demy-colton-release-2018-digital-medicine-report-series-300750564.html
SOURCE EBD Group